首页> Journal for immunotherapy of cancer> Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Colby S,Shemesh

第一单位： Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA. shemesh.colby@gene.com.

作者： Colby S,Shemesh ^[1] ; Pascal,Chanu ^[2] ; Kris,Jamsen ^[3] ; Russ,Wada ^[3] ; Gianluca,Rossato ^[4] ; Francis,Donaldson ^[5] ; Amit,Garg ^[6] ; Helen,Winter ^[6] ; Jane,Ruppel ^[7] ; Xin,Wang ^[8] ; Rene,Bruno ^[2] ; Jin,Jin ^[8] ; Sandhya,Girish ^[8]

作者单位： Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA. shemesh.colby@gene.com. ^[1] Clinical Pharmacology, Modeling and Simulation, Genentech/Roche, Marseille, France. ^[2] Certara Strategic Consulting, Princeton, NJ, USA. ^[3] Clinical Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland. ^[4] Safety Science, Roche Products Ltd, Welwyn Garden City, UK. ^[5] Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.;Present address: Quantitative Pharmacology and Disposition, Seattle Genetics, South San Francisco, CA, USA. ^[6] Bioanalytical Sciences, Genentech Inc., South San Francisco, CA, USA. ^[7] Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA. ^[8]

关键词 Atezolizumab Cancer immunotherapy Clinical pharmacology Exposure-safety Immune checkpoint inhibitor Pediatric oncology Population pharmacokinetics